Text Size:AAA

埃博拉病毒 EBOV (subtype Zaire, strain Mayinga 1976) Glycoprotein / GP 蛋白 (His 標籤)

產品資料評論實驗方法
反應性: EBOV  
應用 : ELISA  WB  IHC-P  IP  
  • Slide 1
40304-T60-50
40304-T60-100
50 µg 
100 µg 
Add to Cart
反應性: EBOV  
應用 : ELISA  IHC-P  FCM  IF  IP  ICC/IF  
    40304-RP01-200
    40304-RP01-100
    200 µg 
    100 µg 
    Add to Cart
    反應性: EBOV  
    應用 : 
    • Slide 1
    40368-MM07-50
    40368-MM07-100
    50 µg 
    100 µg 
    Add to Cart
    反應性: EBOV  
    應用 : ELISA  WB  IHC-P  FCM  IF  IHC-Fr  ICC/IF  
      40094-R106-50
      40094-R106-100
      50 µg 
      100 µg 
      Add to Cart
      反應性: EBOV  
      應用 : ELISA  IHC-P  FCM  IF  IHC-Fr  ICC/IF  
        40094-R301-50
        40094-R301-100
        50 µg 
        100 µg 
        Add to Cart
        反應性: EBOV  
        應用 : ELISA  IHC-P  FCM  IF  ICC/IF  
          40442-MM02-50
          40442-MM02-100
          50 µg 
          100 µg 
          Add to Cart
          反應性: EBOV  
          應用 : ELISA  WB  IHC-P  IP  
            40094-T60-50
            40094-T60-100
            50 µg 
            100 µg 
            Add to Cart
            反應性: EBOV  
            應用 : ELISA  IHC-P  FCM  IF  ICC/IF  
              40442-MM28-50
              40442-MM28-100
              50 µg 
              100 µg 
              Add to Cart
              反應性: EBOV  
              應用 : ELISA  WB  IHC-P  IP  
              • Slide 1
              40368-T60-50
              40368-T60-100
              50 µg 
              100 µg 
              Add to Cart
              反應性: EBOV  
              應用 : ELISA  IHC-P  FCM  IF  IP  ICC/IF  
                40442-RP01-200
                40442-RP01-100
                200 µg 
                100 µg 
                Add to Cart
                反應性: EBOV  
                應用 : WB  IHC-P  IP  
                • Slide 1
                40304-T44-50
                40304-T44-100
                50 µg 
                100 µg 
                Add to Cart
                反應性: EBOV  
                應用 : ELISA  FCM  IF  IP  ICC/IF  
                  40094-RP01-200
                  40094-RP01-100
                  200 µg 
                  100 µg 
                  Add to Cart
                  反應性: EBOV  
                  應用 : WB  IHC-P  IP  
                  • Slide 1
                  40094-T44-50
                  40094-T44-100
                  50 µg 
                  100 µg 
                  Add to Cart
                  反應性: EBOV  
                  應用 : WB  IHC-P  IP  
                  • Slide 1
                  40368-T44-50
                  40368-T44-100
                  50 µg 
                  100 µg 
                  Add to Cart
                  40094-V08H2L-300 
                  40304-V08B1L-300 
                  40304-VCCH1L-300 
                  40304-V02H1L-300 
                  40094-V08B2L-300 
                  40442-V02HL-300 
                  40304-V08HL-300 
                  40442-V08B1L-300 
                  40442-V08H1L-300 
                  40442-V08HL-300 
                  40442-V08H2L-300 
                  40442-V08BL-300 
                  40442-V04HL-300 
                  40094-V02H1L-300 
                  40368-V08BL-300 
                  40094-V08H1L-300 
                  40368-V02HL-300 
                  40368-V02H1L-300 
                  40459-V08HL-300 
                  40459-V08H1L-300 
                  40442-V08H4L-300 

                  EBOV-G/Ebola Glycoprotein Recombinant ProteinRelated Products

                  Related Products

                  Featured Reagent Products

                  EBOV-G/Ebola Glycoprotein protein 研究背景

                  The fourth gene of the EBOV genome encodes a 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). Both GP and sGP have an identical 295-residue N-terminus, however, they have different C-terminal sequences. Recently, great attention has been paid to GP for vaccines design and entry inhibitors isolation. GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . The GP1 subunit contains a mucin domain and a receptor-binding domain (RBD); the GP2 subunit has a fusion peptide, a helical heptad-repeat (HR) region, a transmembrane (TM) domain, and a 4-residue cytoplasmic tail. The RBD of GP1 mediates the interaction of EBOV with cellular receptor (e.g. DC-SIGN/LSIGN, TIM-1, hMGL, NPC1, β-integrins, folate receptor-α, and Tyro3 family receptors), of which TIM1 and NPC1 are essential for EBOV entry; the mucin domain having N- and O-linked glycans enhances the viral attachment to cellular hMGL, and participates in shielding key neutralization epitopes, which helps the virus evades immune elimination. There are large conformation changes of GP2 during membrane fusion, which enhance the insertion of fusion loop into cellular membrane and facilitate the release of viral nucleocapsid core to cytoplasm.

                  EBOV EBOV-G/Ebola Glycoprotein protein 參考資料
                  1. Volchkov VE, et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7.
                  2. Lee JE, et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008 Jul 10;454(7201):177-82. doi: 10.1038/nature07082.
                  3. Hood CL, et al. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol. 2010 Mar;84(6):2972-82. doi: 10.1128/JVI.02151-09.
                  4. Cook JD and Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013 May;9(5):e1003258. doi: 10.1371/journal.ppat.1003258.
                  5. Miller EH and Chandran K. Filovirus entry into cells - new insights. Curr Opin Virol. 2012 Apr;2(2):206-14. doi: 10.1016/j.coviro.2012.02.015.
                  請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”